Spero Therapeutics, which is developing treatments for multi-drug resistant bacterial infections, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2013 and booked $1 million in revenue for the 12 months ended June 30, 2017. It plans to list on the Nasdaq under the symbol SPRO. Spero Therapeutics filed confidentially on August 25, 2017. BofA Merrill Lynch, Cowen & Company, Stifel and Oppenheimer & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.
